KR20060073589A - 항암 치료법을 위한 표적으로서 트레포일 인자 3(ｔｆｆ3) - Google Patents

항암 치료법을 위한 표적으로서 트레포일 인자 3(ｔｆｆ3) Download PDF

Info

Publication number
KR20060073589A
KR20060073589A KR1020067002654A KR20067002654A KR20060073589A KR 20060073589 A KR20060073589 A KR 20060073589A KR 1020067002654 A KR1020067002654 A KR 1020067002654A KR 20067002654 A KR20067002654 A KR 20067002654A KR 20060073589 A KR20060073589 A KR 20060073589A
Authority
KR
South Korea
Prior art keywords
tff3
antibody
cancer
cells
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020067002654A
Other languages
English (en)
Korean (ko)
Inventor
메리 제이. 자낫포어
파블로 가르샤
크리스토프 레인하드
Original Assignee
카이론 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카이론 코포레이션 filed Critical 카이론 코포레이션
Publication of KR20060073589A publication Critical patent/KR20060073589A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020067002654A 2003-08-07 2004-08-05 항암 치료법을 위한 표적으로서 트레포일 인자 3(ｔｆｆ3) Abandoned KR20060073589A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49317303P 2003-08-07 2003-08-07
US60/493,173 2003-08-07
US49843803P 2003-08-28 2003-08-28
US60/498,438 2003-08-28

Publications (1)

Publication Number Publication Date
KR20060073589A true KR20060073589A (ko) 2006-06-28

Family

ID=34138741

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067002654A Abandoned KR20060073589A (ko) 2003-08-07 2004-08-05 항암 치료법을 위한 표적으로서 트레포일 인자 3(ｔｆｆ3)

Country Status (9)

Country Link
US (2) US20080233046A1 (https=)
EP (1) EP1660136A4 (https=)
JP (1) JP2007501616A (https=)
KR (1) KR20060073589A (https=)
AU (1) AU2004263140A1 (https=)
CA (1) CA2534658A1 (https=)
IL (1) IL173333A0 (https=)
MX (1) MXPA06001327A (https=)
WO (1) WO2005013802A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1833991A4 (en) * 2004-12-22 2011-11-16 Auckland Uniservices Ltd TREFOIL FACTORS AND METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES THEREWITH
US7601540B2 (en) * 2006-07-18 2009-10-13 Bristol-Myers Squibb Company Gamma secretase notch biomarkers
US20080199455A1 (en) * 2006-10-03 2008-08-21 Lobie Peter E Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same
ES2332167B1 (es) * 2007-12-04 2010-10-25 Universidad Autonoma De Madrid Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal.
WO2011060040A1 (en) * 2009-11-10 2011-05-19 Abraxis Bioscience, Llc Diagnostic and therapeutic applications of the u6 snrna
GB0920014D0 (en) 2009-11-13 2009-12-30 Medical Res Council Cell sampling device
EP2661620A4 (en) * 2011-01-08 2014-07-16 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL INSUFFICIENCY
WO2025166063A1 (en) 2024-01-31 2025-08-07 Bluerock Therapeutics Lp Igfbp2 in cell culture
CN120209138B (zh) * 2025-05-29 2025-10-03 杭州广科安德生物科技有限公司 Tff3、osm蛋白的抗体及其组合和在结直肠癌诊断中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
US5733748A (en) * 1995-06-06 1998-03-31 Human Genome Sciences, Inc. Colon specific genes and proteins
US6337195B1 (en) * 1995-06-06 2002-01-08 Human Genome Sciences, Inc. Colon specific genes and proteins
DE19701873C1 (de) * 1997-01-21 1998-06-04 Daimler Benz Ag Halterung einer Abgasrückführleitung am Motorgehäuse einer Brennkraftmaschine
US6261562B1 (en) * 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6465611B1 (en) * 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
FR2810297B1 (fr) * 2000-06-16 2002-08-02 Cogema Distributeur automatique de couvercles sur des boites
US6991901B2 (en) * 2001-01-11 2006-01-31 Curagen Corporation Proteins and nucleic acids encoding same
JP2005512510A (ja) * 2001-05-16 2005-05-12 ノバルティス アクチエンゲゼルシャフト 予後および治療標的として乳癌で発現される遺伝子
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE10215320A1 (de) * 2002-04-02 2003-10-23 Metagen Pharmaceuticals Gmbh Verwendungen von TFF3 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
AU2002349786A1 (en) * 2002-06-19 2004-01-06 Japan As Represented By The President Of The University Of Tokyo Method for diagnosis of colorectal tumors
CA2519630A1 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer

Also Published As

Publication number Publication date
WO2005013802A2 (en) 2005-02-17
IL173333A0 (en) 2006-06-11
WO2005013802A3 (en) 2006-03-23
US20050186212A1 (en) 2005-08-25
AU2004263140A1 (en) 2005-02-17
US20080233046A1 (en) 2008-09-25
CA2534658A1 (en) 2005-02-17
EP1660136A4 (en) 2007-02-07
EP1660136A2 (en) 2006-05-31
JP2007501616A (ja) 2007-02-01
MXPA06001327A (es) 2006-05-04

Similar Documents

Publication Publication Date Title
JP7197665B2 (ja) 望ましくない細胞増殖と関連する疾患の治療のための治療剤
US20030194406A1 (en) P-cadherin as a target for anti-cancer therapy
JP2006515742A (ja) 乳癌細胞でのプロテインチロシンキナーゼおよび／またはプロテインチロシンキナーゼ経路と相互作用および／またはモデュレートする化合物の活性を予測するためのポリヌクレオチドの同定
KR20040101502A (ko) 종양의 진단 및 치료 방법 및 이를 위한 조성물
KR20100067089A (ko) Ｔ 세포를 조정하기 위한 방법 및 조성물
CN101932604A (zh) EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
CA2530582A1 (en) Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
US8962808B2 (en) EGFR-related polypeptides and methods of use
US12421514B2 (en) Methods for diagnosing and treating metastatic cancer
KR20060073589A (ko) 항암 치료법을 위한 표적으로서 트레포일 인자 3(ｔｆｆ3)
US7348418B2 (en) Carcinoma-related genes and polypeptides and methods of use thereof
NZ576082A (en) Compositions and methods for therapy and diagnosis of cancer and cancer metastasis involving tpte and cxcr4 expression
US20110287088A1 (en) Modulation of olfml-3 mediated angiogenesis
JPWO2006093337A1 (ja) 癌の予防・治療剤
US20060128644A1 (en) Use of mob-5 in pain
EP2257299B1 (en) Modulation of srpx2-mediated angiogenesis
WO2005123127A2 (en) Methods for treating cancer using prss15 as a target
MX2007012216A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2003102584A2 (en) Semaphorin-like proteins and methods of using same
WO2004047853A2 (en) Methods for the treatment of chronic pain and compositions therefor
HK1172348A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090729

Comment text: Request for Examination of Application

PC1902 Submission of document of abandonment before decision of registration
SUBM Surrender of laid-open application requested